Skip to content
value.today
Clinuvel Pharmaceuticals Limited logo

Clinuvel Pharmaceuticals Limited

CUV.AX
$538 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$64 M
For year ending June-2026
Net income
$23 M
36.0% margin
SEC filing
Employees
—

Clinuvel Pharmaceuticals Limited in brief

Clinuvel Pharmaceuticals Limited is a listed company in the Biotechnology industry, based in Australia. It was founded in 2001. Its last known market value was $538 M (January 2024); there is no current figure. In the year to June 2026 it had sales of $64 M and a net profit of $23 M, about 36 cents of profit for every dollar of sales. Its largest product and service lines by sales in 2026 were Commercial Sales of Goods (90%) and Sales Under Special Access Reimbursement Programs (10%). By market, the largest shares of its 2026 sales came from Ireland (56%) and USA (43%). Its shares trade under the symbol CUV.AX (ASX).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals is a Biopharmaceutical company. The company focused on developing and commercializing treatments for patients with genetic, metabolic and life threatening disorders as well as healthcare solutions for the general population. The headquarters is in Australia.

Clinuvel Pharmaceuticals Limited timeline

3 events, 2001–2018
  1. 2001
  2. 🏁
    · approximate
    Founded
  3. 🔔
    Initial public offering on Australian Securities Exchange as CUV
  4. 2018
  5. •
    Legal Entity Identifier issued
    LEI 5299004VJH3VCYLK6519 registered.

Events of Clinuvel Pharmaceuticals Limited from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$812 M$1.6 B$2.4 B$3.2 B20202021202220232024

World rank over time

▼ down 8,213 places since 2020
2020-01-01: #3938#3,93820202021-01-01: #8646#8,64620212022-01-07: #9638#9,63820222022-12-25: #10246#10,24620222023-07-30: #11548#11,54820232024-01-05: #12151#12,1512024

Rank in Australia: #89 (Jan 2020) · #196 (Jan 2021) · #216 (Jan 2022) · #207 (Dec 2022) · #232 (Jul 2023) · #246 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
36.0%
Operating margin
43.4%
Return on equity
12.3%
Liabilities / assets
7.5%
Revenue growth
+5.2%
R&D / revenue
19.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2024: revenue $58M, net income $23M$58MFY24Fiscal year ending Jun 2025: revenue $61M, net income $23M$61MFY25Fiscal year ending Jun 2026: revenue $64M, net income $23M$64MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2026$64M+5.2%$28M$23M36.0%
Jun 2025$61M+5.5%$27M$23M37.8%
Jun 2024$58M—$29M$23M40.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2026$13M$1M$12M$0.46—
Jun 2025$27M$0M$27M$0.46—
Jun 2024$24M$4M$20M$0.46—

SEC filings

Official filings of Clinuvel Pharmaceuticals Limited with the US Securities and Exchange Commission.

Annual results

Revenue
$64 M
Operating income
$28 M
Net income
$23 M

For year ending June-2026 · source: SEC filing

Balance sheet

Total assets
$204 M
Total liabilities
$15 M
Total equity
$189 M

As of June-2026

Mutual funds holding Clinuvel Pharmaceuticals Limited#

29 funds hold shares worth $13 M. Since their previous reports 12 added shares and 5 sold, buying $1 M net.
Mutual funds holding Clinuvel Pharmaceuticals Limited
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc.567,868$4 M—<0.01%−3.7%Jul 31, 2026
🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc.415,309$3 M—<0.01%+7.9%Jun 30, 2026
🇺🇸 The Asia Pacific Small Company SeriesDimensional Fund Advisors LP243,732$2 M—0.09%+29%Jul 31, 2026
🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc.178,331$1 M—<0.01%+11%Jul 31, 2026
🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP97,682$1 M—<0.01%+113%Jul 31, 2026
🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc.87,840$1 M—0.01%+4.7%May 31, 2026
🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc.54,142$0 M—<0.01%+152%Jul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP53,540$0 M—<0.01%+12%Jul 31, 2026
🇺🇸 Vanguard Pacific Stock Index FundThe Vanguard Group, Inc.52,162$0 M—<0.01%no changeJul 31, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP47,436$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP33,382$0 M—<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.23,430$0 M—0.02%+1.0%Jun 30, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP20,079$0 M—<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc.17,121$0 M—<0.01%−0.1%Jun 30, 2026
🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors18,682$0 M—0.02%+2.1%Jul 31, 2026
🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP10,919$0 M—<0.01%−39%Jul 31, 2026
🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc.8,461$0 M—<0.01%no changeMay 31, 2026
🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP8,605$0 M—<0.01%+171%Jul 31, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC6,680$0 M—0.01%no changeJun 30, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP6,591$0 M—<0.01%no changeJul 31, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP5,455$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust5,143$0 M—0.01%+18%May 31, 2026
🇺🇸 Dimensional International Small Cap Value ETFDimensional Fund Advisors LP4,630$0 M—<0.01%newJul 31, 2026
🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP4,611$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP3,103$0 M—<0.01%no changeJul 31, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC2,335$0 M—0.01%no changeJun 30, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation1,998$0 M—<0.01%no changeJun 30, 2026
🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC760$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP514$0 M—<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Markets and events: Clinuvel Pharmaceuticals Limited#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1,942
0.0% of shares · 1 days to cover

Fails to deliver

  • : 500 shares at $5.07
  • : 54 shares at $5.00
  • : 43 shares at $5.49
  • : 1,810 shares at $5.69
  • : 1,513 shares at $5.56

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Clinuvel Pharmaceuticals Limited scorecard#

Passes 9 of the 11 checks that could be worked out: strongest in shareholder returns (4 of 4), weakest in profitability (2 of 3). Fiscal year 2026.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 2
    • ✓Revenue grew in the newest year5.2%Revenue up 5.2% in fiscal 2026.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year0.46 vs 0.46Diluted EPS 0.46 in fiscal 2026 against 0.46 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 3
    • ✓Profitable in the newest year$23 MNet income $23 M in fiscal 2026.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median43.4%43.4% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%13.4%13.4% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities14.7×Current ratio 14.72 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2026.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns4 of 4
    • ✓Pays a dividendYesPaid dividends in fiscal 2026.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • ✓Dividends under 75% of net income7.2%Dividends were 7.2% of net income in fiscal 2026.
    • ✓Share count up no more than 2% in a year0.7%Diluted shares up 0.7% in fiscal 2026.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • ✓Free cash flow covers dividends and buybacks$12 MFree cash flow $12 M against $2 M paid out in fiscal 2026.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2026#

Worked out from Clinuvel Pharmaceuticals Limited's statements, beside the median of Biotechnology.

Clinuvel Pharmaceuticals Limited: main financial ratios in 2026
Ratio2026Median of peers
Operating margin43.4%-60.5%
Net margin36.0%-68.9%
Return on equity13.4%-61.0%
Revenue growth5.2%15.8%
Free cash flow margin18.4%-61.5%

4of 8on the Piotroski tests of financial strength

Clinuvel Pharmaceuticals Limited: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Clinuvel Pharmaceuticals Limited: statements by fiscal year
PeriodTrendFY 2026to Jun 30, 2026FY 2025to Jun 30, 2025FY 2024to Jun 30, 2024
Income statement
Revenue646158
Cost of revenue111211
Gross profit535047
Research and development121310.0
General and administrative7.46.76.8
Operating expenses252319
Operating income282729
Interest and finance income7.16.14.8
Other non-operating income (expense)0.5−0.10.4
Income before tax333333
Income tax9.510.09.9
Net income attributable to shareholders232323
Earnings per share, basic0.460.460.47
Earnings per share, diluted0.460.460.46
Shares, weighted average (basic)505050
Shares, weighted average (diluted)515051
Balance sheet
Cash and cash equivalents1418—
Short-term investments160127—
Receivables161818
Inventory4.85.7—
Other current assets1.61.7—
Current assets197171—
Property, plant and equipment5.04.5—
Right-of-use (leased) assets1.40.3—
Other intangible assets0.10.1—
Total assets204177—
Accounts payable1.01.7—
Customer deposits160127—
Current liabilities1318—
Lease liabilities (non-current)1.10.1—
Total liabilities1520—
Retained earnings6947—
Shareholders' equity189157135
Total liabilities and equity204177—
Shares outstanding5050—
Cash-flow statement
Share-based compensation1.61.34.1
Cash from operating activities132724
Capital expenditure−1.1−0.2−3.7
Cash from investing activities−26−31−19
Shares bought back—−0.2−0.5
Dividends paid−1.7−1.7−1.6
Cash from financing activities−1.7−1.9−2.1
Change in cash−4.1−5.22.3
Report20-F20-F20-F

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Clinuvel Pharmaceuticals Limited sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Commercial Sales of Goods$58 M90%
  • Sales Under Special Access Reimbursement Programs$6 M10%

Countries and regions

Source: SEC annual report (XBRL data) · as of Jun 30, 2026

Where Clinuvel Pharmaceuticals Limited operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Clinuvel Pharmaceuticals Limited: countries of operation
CountryPresenceRevenue there
🇦🇺 AustraliaHeadquarters2 offices—
🇮🇪 Ireland$36 M56%
🇺🇸 USA$28 M43%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

How Clinuvel Pharmaceuticals Limited compares in Biotechnology

  • Revenue$64 M · higher than 62% of 647
  • Net margin36.0% · higher than 94% of 408
  • Revenue growth5.2% · higher than 49% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Clinuvel Pharmaceuticals Limited🇦🇺$538 M—36.0%+5.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending June-2026
Balance sheet:
As of June-2026
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Clinuvel Pharmaceuticals Limited? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Clinuvel Pharmaceuticals Limited's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Clinuvel Pharmaceuticals Limited? Suggest a correction